OncLive TV

Georges Azzi, MD, discusses the unmet needs the Signatera circulating tumor DNA assay could fulfill in colorectal cancer.

Heinz-Josef Lenz, MD, FACP, discusses the rationale for the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.

Edmund Scott Kopetz, MD, PhD, FACP, discusses the rationale for the ongoing phase 3 BREAKWATER trial in BRAF V600E-mutant metastatic colorectal cancer.

Dhyan Chandra, PhD, discusses the potential to assess mitochondrial function to inform outcomes in prostate cancer.

Claire Harrison, MD, FRCP, FRCPath, discusses current unmet needs in myelofibrosis.

Anna Woloszynska, PhD, discusses the need to assess biological factors of racial disparities in prostate cancer.

Ziad Bakouny, MD, MSc, discusses understanding the biology of translocation renal cell carcinoma.

John Cole, MD, discusses the next steps with tucatinib in HER2-positive breast cancer.

Tycel Jovelle Phillips, MD, discusses ongoing research with BTK inhibitors in mantle cell lymphoma.

Cesar Augusto Perez, MD, discusses the potential utility of KIN-2787 in BRAF-mutated solid tumors.

Sarah Elizabeth Yentz, MD, discusses translating data to real-world clinical practice in renal cell carcinoma.

Matthew S. McKinney, MD, discusses the potential for curative-intent therapies in mantle cell lymphoma.

Michael Choi, MD, discusses future research directions in chronic lymphocytic leukemia.

Aaron T. Gerds, MD, MS, discusses the rationale for the real-world REVEAL study in polycythemia vera.

Laura Finn, MD, discusses the utility of belantamab mafodotin-blmf in late relapsed multiple myeloma.

Tycel Jovelle Phillips, MD, discusses ongoing trials in mantle cell lymphoma.

Jared Weiss, MD, discusses ​the design of the phase 3 KRYSTAL-10 trial in KRAS G12C-mutated unresectable or metastatic colorectal cancer.

Christian Frederick Meyer, MD, PhD, MS, discusses standard treatment options in cardiac angiosarcoma.

Georges Azzi, MD, discusses the rationale for the phase 3 CIRCULATE study in colorectal cancer.

Alexey V. Danilov, MD, PhD, discusses the reduced use of chemoimmunotherapy in chronic lymphocytic leukemia.

Sara M. Tolaney, MD, MPH, sheds light on zanidatamab and the data reported with the agent in combination with chemotherapy for the treatment of patients with HER2-positive breast cancer. 

Leonard G. Gomella, MD, discusses the challenges of optimizing prostate-specific antigen as a biomarker in prostate cancer.

Haythem Y. Ali, MD, member, Henry Ford Cancer Institute, Henry Ford Health System, discusses the need to understand real-world disparities with BRCA testing referrals and uptake in patients with triple-negative breast cancer.

Mario Spaggiari, MD, discusses surgical strategies to improve liver remnants in colorectal cancer with liver metastases.

Ruben A. Mesa, MD, discusses JAK inhibitors and other promising agents in the myelofibrosis therapeutic landscape.

Jan A. Burger, MD, PhD, discusses the benefit of combination therapy in patients with chronic lymphocytic leukemia.

Danielle M. Brander, MD, discusses the role of achieving minimal residual disease negativity with venetoclax-based regimens in chronic lymphocytic leukemia.

Deborah L. Toppmeyer, MD, discusses sequencing therapy in HER2-positive breast cancer.

Ian E. Krop, MD, PhD, discusses progress made in 2021 in the management of HER2-positive breast cancer.

Adam M. Brufsky, MD, PhD, FACP, discusses the unique mechanism of action of zanidatamab and encouraging efficacy observed in patients with HER2-positive breast cancer.